Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Colorectal Neoplasms

abstract

  • Tremelimumab did not demonstrate clinically meaningful single-agent activity in this patient population, although the number of survivors at 6 months and the one patient with confirmed partial response are potentially interesting. Further study of tremelimumab in combination with other agents may be warranted.

publication date

  • July 20, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.28.3994

PubMed ID

  • 20498386

Additional Document Info

start page

  • 3485

end page

  • 90

volume

  • 28

number

  • 21